Performance vs S&P 500

03
Tracked Q2 2025–Q2 2026 -3.4%
S&P 500 total return (same window) +21.7%
Excess return -25.1%

Annualized: -3.4% · S&P 500: +21.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 97.0% · Options excluded: 0.0%

Sector breakdown

04
Industrials 33.9%
Healthcare 27.8%
Other/Unmapped 38.4%

Full portfolio 4 positions

05
Type Streak 8Q trend
EVLV Evolv Technologies Holdings, Inc. - Class A Common Stock $26,622,000 33.89% 4,590,000 $-1,147,500
Unknown issuer (CUSIP: Y4000A102) $25,405,896 32.34% 915,198 $17,361,306
RXRX Recursion Pharmaceuticals, Inc. - Class A Common Stock $21,803,910 27.76% 5,941,120 $3,564,672
DFTX Definium Therapeutics, Inc. - Common Shares $4,720,464 6.01% 100,350 $2,823,849

Top movers (QoQ)

10
SecurityActionShares ΔValue Δ
· Price move only +0 +$17.4M
RXRX Price move only +0 +$3.6M
DFTX Price move only +0 +$2.8M
EVLV Price move only +0 -$1.1M

Exited positions

11

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarterShares beforeValue beforePrice since exit
RKLB Sept. 30, 2025 1,083,053 $38,740,806 54.3%
RKLB (filed as RKLBXXXX) June 30, 2025 1,377,943 $24,637,621 106.7%
MNMD March 31, 2026 100,350 $1,343,687 No longer tracked
ROIV Dec. 31, 2025 3,875 $58,629 64.6%